8.52012
Fmoc-Lys(Boc)-OH
Novabiochem®
Synonyme(s) :
Fmoc-Lys(Boc)-OH, N-α-Fmoc-N-ε-t.-Boc-L-lysine
Sélectionner une taille de conditionnement
A propos de cet article
SMILES string
N(C(CCCCNC(=O)OC(C)(C)C)C(=O)O)C(=O)OCC1c2c(cccc2)c3c1cccc3
InChI
1S/C26H32N2O6/c1-26(2,3)34-24(31)27-15-9-8-14-22(23(29)30)28-25(32)33-16-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,21-22H,8-9,14-16H2,1-3H3,(H,27,31)(H,28,32)(H,29,30)
InChI key
UMRUUWFGLGNQLI-UHFFFAOYSA-N
product line
Novabiochem®
assay
≥98% (TLC), ≥98.0% (acidimetric), ≥99.0% (HPLC)
form
powder
reaction suitability
reaction type: Fmoc solid-phase peptide synthesis
manufacturer/tradename
Novabiochem®
mp
123-130 °C
application(s)
peptide synthesis
functional group
Boc, amine
storage temp.
2-30°C
Quality Level
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
General description
Associated Protocols and Technical Articles
Fmoc-amino acids for Peptide Production
Cleavage and Deprotection Protocols for Fmoc SPPS
Application
- Pharmacokinetics of Tizanidine in Muscle Spasticity: A comprehensive review on Tizanidine covers its pharmacological advancements and therapeutic applications, particularly focusing on muscle spasticity. This highlights the relevance of high-purity Tizanidine-D₄ hydrochloride in creating precise and reproducible pharmacokinetic profiles (Zhu et al., 2024).
- Stable Isotope-Labeled Tizanidine for Bioanalytical Method Development: The development and validation of bioanalytical methods for monitoring drug interactions and metabolism extensively utilize Tizanidine-D₄ HCl. The isotopic labeling aids in accurate quantification and identification, enhancing the reliability of pharmacokinetic and pharmacodynamic studies (Chen et al., 2024).
- Tizanidine-D₄ Hydrochloride Solution for Receptor Binding Studies: The application of Tizanidine-D₄ in receptor binding studies is inferred from research exploring its withdrawal effects and the pharmacological interventions required, suggesting its utility in detailed receptor interaction studies in clinical settings (Tanimura et al., 2024).
Analysis Note
Appearance of substance (visual): powder
Colour index (0,5 M in DMF): ≤ 150 Hazen
Identity (IR): passes test
Enantiomeric purity: ≥ 99.8 % (a/a)
Purity (HPLC): ≥ 99.0 % (a/a)
Fmoc-ß-Ala-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-ß-Ala-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys(Boc)-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys-OH (HPLC): ≤ 0.1 % (a/a)
Assay free amino acid (GC): ≤ 0.2 %
Purity (TLC(011A)): ≥ 98 %
Purity (TLC(0811)): ≥ 98 %
Solubility (25 mmole in 50 ml DMF): clearly soluble
Assay (acidimetric): ≥ 98.0 %
Water (K. F.): ≤ 2.0 %
Ethyl acetate (HS-GC): ≤ 0.5 %
Acetate (IC): ≤ 0.02 %
To see the solvent systems used for TLC of Novabiochem® products please click here.
Other Notes
Legal Information
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique